XU Yanhua, GUO Yinshi. Research Progress of Icatibant in the Treatment of Hereditary Angioedema[J]. Journal of Rare Diseases, 2025, 4(3): 287-293. DOI: 10.12376/j.issn.2097-0501.2025.03.002
Citation:
XU Yanhua, GUO Yinshi. Research Progress of Icatibant in the Treatment of Hereditary Angioedema[J]. Journal of Rare Diseases, 2025, 4(3): 287-293. DOI: 10.12376/j.issn.2097-0501.2025.03.002
XU Yanhua, GUO Yinshi. Research Progress of Icatibant in the Treatment of Hereditary Angioedema[J]. Journal of Rare Diseases, 2025, 4(3): 287-293. DOI: 10.12376/j.issn.2097-0501.2025.03.002
Citation:
XU Yanhua, GUO Yinshi. Research Progress of Icatibant in the Treatment of Hereditary Angioedema[J]. Journal of Rare Diseases, 2025, 4(3): 287-293. DOI: 10.12376/j.issn.2097-0501.2025.03.002
Research Progress of Icatibant in the Treatment of Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic disorder, typically managed with on-demand medications during acute attacks. Clinical trials and real-world studies have demonstrated the efficacy and safety of icatibant in treating acute HAE attacks. This article aims to summarize research findings on icatibant in HAE treatment, providing a reference for its clinical application.
DownLoad: